Loading
SX-682 is an experimental tablet from Syntrix Pharmaceuticals that blocks the CXCR1 and CXCR2 receptors on immune-suppressing cells. It is in phase 2 trials, alone or with other medicines, in prostate cancer, lung cancer and other cancers.
SX-682 is Syntrix Pharmaceuticals' CXCR1/2 inhibitor. Registered trials in OnCo include NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer; NCT05570825 and NCT07322341, University of Washington trials with pembrolizumab and with atezolizumab in non-small cell lung cancer; and NCT06149481, a National Cancer Institute trial combining it with a vaccine, retifanlimab and N-803 in metastatic colorectal cancer. NCI SBIR awards to Syntrix in 2026 fund studies in myelodysplastic syndromes and melanoma.
A dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which Syntrix Pharmaceuticals describes as inactivating the myeloid-derived suppressor cells and neutrophils that shield tumours from T cells and natural killer cells.
1.SX-682 slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SX-682" OR ABSTRACT:"SX-682") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SX-682, not a curated reading list.
Shares Colon cancer (adenocarcinoma of the colon), Rectal cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Rectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Rectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/